Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas

Kyeung Min Joo, Shi Yean Kim, Xun Jin, Sang Yong Song, Doo Sik Kong, Jung Ii Lee, Ji Won Jeon, Mi Hyun Kim, Bong Gu Kang, Yong Jung, Juyoun Jin, Seung Chyul Hong, Woong Yang Park, Dong Sup Lee, Hyunggee Kim, Do Hyun Nam

Research output: Contribution to journalArticle

265 Citations (Scopus)

Abstract

A number of recent reports have demonstrated that only CD133-positive cancer cells of glioblastoma multiforme (GBM) have tumor-initiating potential. These findings raise an attractive hypothesis that GBMs can be cured by eradicating CD133-positive cancer stem cells (CSCs), which are a small portion of GBM cells. However, as GBMs are known to possess various genetic alterations, GBMs might harbor heterogeneous CSCs with different genetic alterations. Here, we compared the clinical characteristics of two GBM patient groups divided according to CD133-positive cell ratios. The CD133-low GBMs showed more invasive growth and gene expression profiles characteristic of mesenchymal or proliferative subtypes, whereas the CD133-high GBMs showed features of cortical and well-demarcated tumors and gene expressions typical of proneuronal subtype. Both CD133-positive and CD133-negative cells purified from four out of six GBM patients produced typical GBM tumor masses in NOD-SCID brains, whereas brain mass from CD133-negative cells showed more proliferative and angiogenic features compared to that from CD133-positive cells. Our results suggest, in contrast to previous reports that only CD133-positive cells of GBMs can initiate tumor formation in vivo CD133-negative cells also possess tumor-initiating potential, which is indicative of complexity in the identification of cancer cells for therapeutic targeting.

Original languageEnglish
Pages (from-to)808-815
Number of pages8
JournalLaboratory Investigation
Volume88
Issue number8
DOIs
Publication statusPublished - 2008 Aug 1

Fingerprint

Glioblastoma
Neoplasms
Neoplastic Stem Cells
Brain
Transcriptome
Gene Expression
Growth

Keywords

  • Cancer stem cell
  • CD133
  • Clinical manifestation
  • Gene expression profile
  • Glioblastoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Joo, K. M., Kim, S. Y., Jin, X., Song, S. Y., Kong, D. S., Lee, J. I., ... Nam, D. H. (2008). Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Laboratory Investigation, 88(8), 808-815. https://doi.org/10.1038/labinvest.2008.57

Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. / Joo, Kyeung Min; Kim, Shi Yean; Jin, Xun; Song, Sang Yong; Kong, Doo Sik; Lee, Jung Ii; Jeon, Ji Won; Kim, Mi Hyun; Kang, Bong Gu; Jung, Yong; Jin, Juyoun; Hong, Seung Chyul; Park, Woong Yang; Lee, Dong Sup; Kim, Hyunggee; Nam, Do Hyun.

In: Laboratory Investigation, Vol. 88, No. 8, 01.08.2008, p. 808-815.

Research output: Contribution to journalArticle

Joo, KM, Kim, SY, Jin, X, Song, SY, Kong, DS, Lee, JI, Jeon, JW, Kim, MH, Kang, BG, Jung, Y, Jin, J, Hong, SC, Park, WY, Lee, DS, Kim, H & Nam, DH 2008, 'Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas', Laboratory Investigation, vol. 88, no. 8, pp. 808-815. https://doi.org/10.1038/labinvest.2008.57
Joo, Kyeung Min ; Kim, Shi Yean ; Jin, Xun ; Song, Sang Yong ; Kong, Doo Sik ; Lee, Jung Ii ; Jeon, Ji Won ; Kim, Mi Hyun ; Kang, Bong Gu ; Jung, Yong ; Jin, Juyoun ; Hong, Seung Chyul ; Park, Woong Yang ; Lee, Dong Sup ; Kim, Hyunggee ; Nam, Do Hyun. / Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. In: Laboratory Investigation. 2008 ; Vol. 88, No. 8. pp. 808-815.
@article{043d54d39dd648e0b4717cd9565cab0e,
title = "Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas",
abstract = "A number of recent reports have demonstrated that only CD133-positive cancer cells of glioblastoma multiforme (GBM) have tumor-initiating potential. These findings raise an attractive hypothesis that GBMs can be cured by eradicating CD133-positive cancer stem cells (CSCs), which are a small portion of GBM cells. However, as GBMs are known to possess various genetic alterations, GBMs might harbor heterogeneous CSCs with different genetic alterations. Here, we compared the clinical characteristics of two GBM patient groups divided according to CD133-positive cell ratios. The CD133-low GBMs showed more invasive growth and gene expression profiles characteristic of mesenchymal or proliferative subtypes, whereas the CD133-high GBMs showed features of cortical and well-demarcated tumors and gene expressions typical of proneuronal subtype. Both CD133-positive and CD133-negative cells purified from four out of six GBM patients produced typical GBM tumor masses in NOD-SCID brains, whereas brain mass from CD133-negative cells showed more proliferative and angiogenic features compared to that from CD133-positive cells. Our results suggest, in contrast to previous reports that only CD133-positive cells of GBMs can initiate tumor formation in vivo CD133-negative cells also possess tumor-initiating potential, which is indicative of complexity in the identification of cancer cells for therapeutic targeting.",
keywords = "Cancer stem cell, CD133, Clinical manifestation, Gene expression profile, Glioblastoma",
author = "Joo, {Kyeung Min} and Kim, {Shi Yean} and Xun Jin and Song, {Sang Yong} and Kong, {Doo Sik} and Lee, {Jung Ii} and Jeon, {Ji Won} and Kim, {Mi Hyun} and Kang, {Bong Gu} and Yong Jung and Juyoun Jin and Hong, {Seung Chyul} and Park, {Woong Yang} and Lee, {Dong Sup} and Hyunggee Kim and Nam, {Do Hyun}",
year = "2008",
month = "8",
day = "1",
doi = "10.1038/labinvest.2008.57",
language = "English",
volume = "88",
pages = "808--815",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas

AU - Joo, Kyeung Min

AU - Kim, Shi Yean

AU - Jin, Xun

AU - Song, Sang Yong

AU - Kong, Doo Sik

AU - Lee, Jung Ii

AU - Jeon, Ji Won

AU - Kim, Mi Hyun

AU - Kang, Bong Gu

AU - Jung, Yong

AU - Jin, Juyoun

AU - Hong, Seung Chyul

AU - Park, Woong Yang

AU - Lee, Dong Sup

AU - Kim, Hyunggee

AU - Nam, Do Hyun

PY - 2008/8/1

Y1 - 2008/8/1

N2 - A number of recent reports have demonstrated that only CD133-positive cancer cells of glioblastoma multiforme (GBM) have tumor-initiating potential. These findings raise an attractive hypothesis that GBMs can be cured by eradicating CD133-positive cancer stem cells (CSCs), which are a small portion of GBM cells. However, as GBMs are known to possess various genetic alterations, GBMs might harbor heterogeneous CSCs with different genetic alterations. Here, we compared the clinical characteristics of two GBM patient groups divided according to CD133-positive cell ratios. The CD133-low GBMs showed more invasive growth and gene expression profiles characteristic of mesenchymal or proliferative subtypes, whereas the CD133-high GBMs showed features of cortical and well-demarcated tumors and gene expressions typical of proneuronal subtype. Both CD133-positive and CD133-negative cells purified from four out of six GBM patients produced typical GBM tumor masses in NOD-SCID brains, whereas brain mass from CD133-negative cells showed more proliferative and angiogenic features compared to that from CD133-positive cells. Our results suggest, in contrast to previous reports that only CD133-positive cells of GBMs can initiate tumor formation in vivo CD133-negative cells also possess tumor-initiating potential, which is indicative of complexity in the identification of cancer cells for therapeutic targeting.

AB - A number of recent reports have demonstrated that only CD133-positive cancer cells of glioblastoma multiforme (GBM) have tumor-initiating potential. These findings raise an attractive hypothesis that GBMs can be cured by eradicating CD133-positive cancer stem cells (CSCs), which are a small portion of GBM cells. However, as GBMs are known to possess various genetic alterations, GBMs might harbor heterogeneous CSCs with different genetic alterations. Here, we compared the clinical characteristics of two GBM patient groups divided according to CD133-positive cell ratios. The CD133-low GBMs showed more invasive growth and gene expression profiles characteristic of mesenchymal or proliferative subtypes, whereas the CD133-high GBMs showed features of cortical and well-demarcated tumors and gene expressions typical of proneuronal subtype. Both CD133-positive and CD133-negative cells purified from four out of six GBM patients produced typical GBM tumor masses in NOD-SCID brains, whereas brain mass from CD133-negative cells showed more proliferative and angiogenic features compared to that from CD133-positive cells. Our results suggest, in contrast to previous reports that only CD133-positive cells of GBMs can initiate tumor formation in vivo CD133-negative cells also possess tumor-initiating potential, which is indicative of complexity in the identification of cancer cells for therapeutic targeting.

KW - Cancer stem cell

KW - CD133

KW - Clinical manifestation

KW - Gene expression profile

KW - Glioblastoma

UR - http://www.scopus.com/inward/record.url?scp=48749114753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48749114753&partnerID=8YFLogxK

U2 - 10.1038/labinvest.2008.57

DO - 10.1038/labinvest.2008.57

M3 - Article

C2 - 18560366

AN - SCOPUS:48749114753

VL - 88

SP - 808

EP - 815

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 8

ER -